In case you missed it, a new article in Inside Health Policy reported that “Investors for eight major drug companies will vote throughout the spring on 11 proposals aimed at reducing the use of common drug patent practices and pharmaceutical lobbying activities
The House Ways and Means Committee will vote tomorrow, May 8, on legislation that will include a so-called “delinking” policy in Medicare. To be clear, the “delinking” policy proposal is backed by Big Pharma because it will significantly boost profits.
Pharmacy benefit companies are strong proponents of a highly functioning biosimilar market. Bringing more biosimilars to market, over time, will allow PBMs to more effectively leverage competition to reduce drug costs for health plan sponsors and patients. As biosimilar competition
“In effect, the era of high list prices and high rebates for insulin is over” In case you missed it, Alex Brill, founder and CEO of Matrix Global Advisors (MGA) and former policy director and chief economist for the House
In case you missed it, PCMA President and CEO JC Scott joined Prime Therapeutics’ webinar Beyond the Script: PBM Hot Topics in D.C. to discuss how pharmacy benefit companies innovate and deliver value for patients. The panel was moderated by Mostafa
As independent pharmacies conduct a “Fly-In” in Washington D.C this week, they will undoubtedly double-down on support for policies targeting pharmacy benefit companies that would have profound negative consequences for employers, taxpayers, and patients. It’s important for lawmakers to consider
The vast majority of employers and public health programs voluntarily work with pharmacy benefit companies to manage pharmacy benefits. So, what happens when a health plan doesn’t use a pharmacy benefit company? A recent Department of Labor (DOL) Office of the
As Congress returns to Washington, Ike Brannon, senior fellow at the Jack Kemp Foundation, explains how state and federal efforts to undermine the role of pharmacy benefit managers (PBMs) would do nothing to reduce drug costs in a new op-ed
The pharmacy benefit company market is competitive and diverse, with more than 70 full-service PBMs of varying size operating across the country. These companies differentiate themselves through the services, contract terms, and products they offer. Across this competitive industry is a common mission
(Washington, D.C.) — Today, representative organizations of America’s pharmaceutical supply and payment chain, including prescription and over-the-counter brand and generic manufacturers; pharmacies and pharmacists across all practice settings, including health systems and hospitals, community, specialty, and managed care; supermarkets; wholesalers; pharmaceutical
©2024 PCMA. All Rights Reserved.
